Investor Stock List
Ranked #3,293 of 8,699 institutional investors

Lynx1 Capital Management LP

Dorado, PR

$587M
US stock portfolio at live prices · today +$3.0M (+0.51%)
Live prices, last trade 11:28 AM ET
Value at quarter end (Q3 2026)
$646M
Change from Q2 2026
−$219.4M (−25.35%)
Positions
28 · 6 new, 1 sold out
Filed
Nov 16, 2026

Not counted in the ranking: none$315M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
STOK 18.1%CGEM 13.8%DTIL 3.43%KRRO 3.33%CCCC 3.19%
StockSharesValue, live% of portfoliovs Q2 2026
STOK Stoke Therapeutics, Inc.3,896,169$106M18.1%Reduced −4%
CGEM Cullinan Therapeutics, Inc.8,963,500$80.9M13.8%Unchanged
DTIL Precision BioSciences, Inc.2,758,215$20.1M3.43%Added +190%
KRRO Korro Bio, Inc.1,544,980$19.5M3.33%Added +0%
CCCC C4 Therapeutics, Inc.7,530,915$18.7M3.19%Added +3%
AGIO Agios Pharmaceuticals, Inc.472,606$13.5M2.29%Reduced −86%
PASG Passage Bio, Inc.673,759$2.4M0.40%Unchanged
NEUP Neuphoria Therapeutics Inc.875,328$2.1M0.35%Unchanged
TRDA Entrada Therapeutics, Inc.278,606$1.3M0.21%Added +56%
TCRX TScan Therapeutics, Inc.8,019,148$1.2M0.21%Unchanged
KZIA Kazia Therapeutics Limited225,800$1.1M0.19%New
PLRX Pliant Therapeutics, Inc.1,798,070$1.1M0.18%Unchanged
HOWL Werewolf Therapeutics, Inc.657,786$618K0.11%Unchanged
XNCR Xencor, Inc.18,194$612K0.10%Unchanged
SRZN Surrozen, Inc.20,000$590K0.10%New
DYN Dyne Therapeutics, Inc.25,000$398K<0.1%New
IMCR Immunocore Holdings plc14,300$381K<0.1%New
YARW Yarrow Bioscience, Inc.22,000$306K<0.1%New
DNLI Denali Therapeutics Inc.11,658$218K<0.1%Unchanged
PRME Prime Medicine, Inc.45,000$174K<0.1%New
ABSI Absci Corporation21,245$163K<0.1%Unchanged
BOLT Bolt Biotherapeutics, Inc.30,800$155K<0.1%Unchanged
TRAW Traws Pharma, Inc.559,470$120K<0.1%Unchanged
FHTX Foghorn Therapeutics Inc.61,588$107K<0.1%Unchanged
AVTX Avalo Therapeutics, Inc.10,100$68K<0.1%Unchanged
NUVB Nuvation Bio Inc.16,029$61K<0.1%Unchanged
EPRX Eupraxia Pharmaceuticals Inc.10,000$59K<0.1%Unchanged
IKT Inhibikase Therapeutics, Inc.584$763<0.1%Reduced −97%

Sold out in Q3 2026

StockShares held at Q2 2026Worth today
CGON CG Oncology, Inc.31,391$2.6M